You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 1, January 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of Dermatology
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Month in Archives of Dermatology

Arch Dermatol. 2003;139:9.

Amelioration of Body Odor After Intracutaneous Axillary Injection of Botulinum Toxin A

Body odor is a common phenomenon, most often noted in the axillary region where it is associated with axillary sweat secretion. Botulinum toxin A has previously been shown effective for treatment of axillary hyperhidrosis through chemodenervation of the eccrine sweat glands. Heckmann et al demonstrate that it may also ameliorate axillary odor, possibly through chemodenervation of the apoeccrine sweat glands.

(SEE ARTICLE)


Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of Lupus Erythematosus

The cutaneous lesions of lupus erythematosus may be chronic and quite disfiguring. Conventional first-line therapies include antimalarial agents and aggressive photoprotection. Thalidomide, an anti-inflammatory immunomodulator, represents a promising therapeutic option for those patients with refractory, antimalarial-resistant cutaneous lupus erythematosus. In this retrospective chart review, Housman et al confirm the efficacy of low-dose thalidomide in this clinical setting and further address the question of the optimal dosing regimen.

(SEE ARTICLE)


Ultraviolet Radiation in Alpine Skiing: Magnitude of Exposure and Importance of Regular Protection

As participation in outdoor alpine sports increases, the potential for exposure to damaging UV-A and UV-B radiation increases among the sporting population. Rigel et al used digital dosimetry at typical skiing elevations to demonstrate that alpine skiers are regularly exposed to measurable erythemogenic and suberythemogenic doses of UV radiation at levels that may increase their lifetime risk of cutaneous malignancies.

(SEE ARTICLE)


Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases

Toxic epidermal necrolysis (TEN) is a rare, life-threatening disease manifested by rapid onset of sheetlike epidermal detachment. The primary event in TEN may be extensive Fas-mediated keratinocyte apoptosis. The low prevalence of TEN precludes randomized clinical trials, and no proven and widely accepted treatment exists. The observation that antibodies present in pooled purified human immunoglobulin block Fas-mediated apoptosis has led to the introduction of high-dose intravenous immunoglobulin treatment into the therapy for TEN. Prins et al offer further evidence that early infusion of high-dose intravenous immunoglobulin is safe, well tolerated, and likely to be of benefit in improving the survival of patients with TEN.


Epidermal detachment at the time of initiation of intravenous immunoglobulin infusion.


(SEE ARTICLE)


The Actinic (Solar) Keratosis: A 21st-Century Perspective

In this review, Fu and Cockerell reinforce the widening acceptance of actinic keratosis as an early cutaneous malignant process. Actinic keratosis is described as a clinical manifestation of UV radiation–induced neoplastic transformation of keratinocytes that is on a continuum that may extend to full-blown squamous cell carcinoma with the attendant morbidity and even mortality. A naming system is proposed that more accurately reflects the early malignant nature of this lesion.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.